Claude Messiaen

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

Pierre Quartier, Florence Allantaz, Rolando Cimaz et al. · Annals of the Rheumatic Diseases · 2010 · 543 citations · Full text

Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: an estimate based on a record linkage of two national databases

Geneviève Baujat, Rémy Choquet, S. Bouée et al. · Orphanet Journal of Rare Diseases · 2017 · 109 citations · Full text

A methodology for a minimum data set for rare diseases to support national centers of excellence for healthcare and research

Rémy Choquet, Meriem Maaroufi, Albane de Carrara et al. · Journal of the American Medical Informatics Association · 2014 · 94 citations · Full text

Prognostic Factors From an Epidemiologic Evaluation of Fibrous Dysplasia of Bone in a Modern Cohort: The FRANCEDYS Study

Johanna Benhamou, D. Gensburger, Claude Messiaen et al. · Journal of Bone and Mineral Research · 2016 · 54 citations · Full text

CEMARA an information system for rare diseases

Paul Landais, Claude Messiaen, Ana Rath et al. · Studies in health technology and informatics · 2010 · 32 citations

Engineering, Labelled Reference Centres, Information System +19